The burden of rhinitis in Australia

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Real life treatment of rhinitis

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  Rhinitis allergic

Population studied

• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  50000

Study design details

• Main study objective:
  To evaluate the burden of rhinitis on healthcare in Australia by assessing the real life treatment of rhinitis using prescribing and over the counter information, and the effect of introducing Dymista to the Australian market
• Outcomes:
  1) To assess the number of therapies (single vs. multiple drugs) used to treat rhinitis in Australia2) To describe the combination of therapies used to treat rhinitis in Australia3) To investigate the influence of OTC medications on the count and combination of therapies used to treat rhinitis in Australia, 4) To investigate the seasonality of rhinitis treatment patterns5) To estimate the cost of rhinitis treatment in Australia6) To investigate the relationship between rhinitis treatment patterns and co-morbid asthma treatment
• Data analysis plan:
  • Count of therapies will be reported as means and standard deviation SD, and/or median and inter-quartile range (25th and 75th percentiles) along with minimum and maximum values. Moreover, count of therapies will be presented as single, multiple and total number of therapies. • Within the multiple therapy patients group, the combination of different drug will be reported as absolute numbers as well as proportions and percentages.• Prescribed and over-the-counter medications will be reported as absolute numbers as well as proportions and percentages. • Time series analysis will be used to explore seasonality of rhinitis treatment patterns over the study period• The cost of rhinitis treatment will be reported as mean and median purchase (in Austrian dollars) along with their inter-quartile range and minimum and maximum values of purchases.